Physician profile
Fernand Bteich
NPI 1770004269
$3,817.04
in general payments reported to CMS, 2019-2025
19 companies · $354 in 2025
The $354 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $358 · 2022: $1,125 · 2023: $1,656 · 2024: $325 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.89 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $891.39 | 2022-2023 | |
| Abbvie INC. | $581.06 | 2023-2025 | Venclexta, Epkinly |
| Gilead Sciences, INC. | $350.00 | 2022-2023 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $259.31 | 2021 | |
| Daiichi Sankyo INC. | $248.66 | 2022-2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $246.82 | 2023 | Opdivo, Reblozyl |
| Seagen INC. | $237.92 | 2023 | Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $201.67 | 2022 | |
| Exelixis INC. | $174.00 | 2024 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $146.51 | 2024-2025 | |
| Genentech USA, INC. | $116.45 | 2025 | |
| Adaptive Biotechnologies Corporation | $103.83 | 2022 | |
| Alexion Pharmaceuticals, INC. | $99.00 | 2021 | |
| Genentech, INC. | $79.00 | 2025 | |
| Medtronic, INC. | $42.11 | 2025 | Emprint |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $21.69 | 2025 | Qinlock, Romvimza |
| Merck Sharp & Dohme LLC | $17.62 | 2025 | Keytruda |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernand Bteich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.